Trump administration probe could upend widely used transgender youth treatment guidelines

The organization widely regarded as the leading authority on transgender medical treatment is facing allegations from the Federal Trade Commission that it built influential treatment guidelines for minors on evidence its own leaders privately acknowledged was limited and uncertain.

The complaint, filed in a Texas federal court by the Federal Trade Commission and the attorneys general of Alaska, Iowa, Nebraska and Texas, accuses World Professional Association for Transgender Health (WPATH) of developing and promoting guidance that healthcare providers relied upon when recommending puberty blockers, cross-sex hormones and sex-change procedures for minors.

[…]

Kurt Miceli, chief medical officer for Do No Harm, a medical ethics advocacy organization, said the allegations raise serious questions about how the organization’s guidelines were developed.

“The conflicts of interest that are within the standards of care are significant, and again, not brought to light, and this is part of that deception, and the concern that WPATH has sort of stated that the science is there behind pediatric medical transition when it is not.”

Read more at Fox News.